An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis - Atlantic Healthcare

HEALTHCARE PRACTITIONERS
CONTACT US

About
Research
Therapeutic Focus
Pipeline
Investors
News
- Conferences

Search

HEALTHCARE PRACTITIONERS
CONTACT US

P. Miner JR, M. Wedel, B. Bane & J. Bradley

Aliment Pharmacol Ther (2004) 19: 281-286

Recent Posts

Atlantic Healthcare Announces Results from Phase 3 Trial of Alicaforsen Enema for Orphan-Designated Pouchitis
31st July 2019
Atlantic Healthcare plc acquires global rights to renzapride for the treatment of gastrointestinal motility disorders
26th June 2019
Atlantic Healthcare to attend DDW in San Diego, May 18-21
1st May 2019
Atlantic Healthcare to attend BIO-Europe Spring in Vienna, March 23-25
12th March 2019
Atlantic Healthcare to present at the Piper Jaffray 2018 Healthcare Conference in New York on November 27 (10.10 – 10.30 ET)
26th November 2018

Follow

Privacy Preference Center

Privacy Preferences